Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tandem Diabetes Care, Inc. - Common Stock (NQ:TNDM)

15.15 +0.05 (+0.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tandem Diabetes Care, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
t:slim X2™ Insulin Pump Now Available with Abbott’s FreeStyle Libre® 3 Plus Sensor in the United States
From Tandem Diabetes Care, Inc.
Via Business Wire
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation – TNDM
From The Rosen Law Firm, P.A.
Via Business Wire
TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
Tandem Diabetes Care to Announce Third Quarter 2025 Financial Results on November 6, 2025
From Tandem Diabetes Care, Inc.
Via Business Wire
Tandem t:slim X2 Insulin Pump Now Compatible With Lyumjev Ultra-Rapid Acting Insulin in the United States
From Tandem Diabetes Care, Inc.
Via Business Wire
TNDM Investors Have Opportunity to Join Tandem Diabetes Care, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Tandem Diabetes Care Announces Publication Showing Adults With Type 2 Diabetes Benefit from Automated Insulin Delivery Regardless of C-Peptide Levels
From Tandem Diabetes Care
Via Business Wire
TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
Rosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation – TNDM
From Rosen Law Firm
Via Business Wire
Tandem t:slim Mobile App Now Authorized by Health Canada for iPhone and Android Phones
From Tandem Diabetes Care, Inc.
Via Business Wire
Securities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
Tandem Diabetes Care, Inc. (TNDM) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
Securities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
Tandem Diabetes Care Issues Voluntary Medical Device Correction for Select t:slim X2 Insulin Pumps
From Tandem Diabetes Care, Inc.
Via Business Wire
Tandem Diabetes Care Announces Second Quarter 2025 Financial Results and Provides 2025 Annual Guidance
From Tandem Diabetes Care, Inc.
Via Business Wire
Tandem Diabetes Care Announces Upcoming Conference Participation
From Tandem Diabetes Care, Inc.
Via Business Wire
Artificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy Creating a Multi-Billion Dollar Revenue Opportunity
EQNX::TICKER_START (OTCQB:AVAI),(NYSE:ABT),(NASDAQ:DXCM),(NASDAQ:IRTC),(NASDAQ:TNDM) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Tandem Diabetes Care to Announce Second Quarter 2025 Financial Results on August 6, 2025
From Tandem Diabetes Care, Inc.
Via Business Wire
Tandem Diabetes Care Announces t:slim X2™ Insulin Pump Compatibility with Abbott’s FreeStyle Libre® 3 Plus Sensor in the United States
From Tandem Diabetes Care, Inc.
Via Business Wire
Tandem Diabetes Care Announces Agreement with Abbott for Integration of Automated Insulin Delivery Systems with Future Glucose-Ketone Sensor
From Tandem Diabetes Care, Inc.
Via Business Wire
Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TNDM),(NYSE:NVO),(NASDAQ:PODD),(NYSE:MDT) EQNX::TICKER_END 
Via FinancialNewsMedia
Tandem Diabetes Care Announces Upcoming Conference Presentations
From Tandem Diabetes Care, Inc.
Via Business Wire
Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities
From FN Media Group LLC
Via GlobeNewswire
Tandem Diabetes Care Announces First Quarter 2025 Financial Results
From Tandem Diabetes Care, Inc.
Via Business Wire
Tandem Diabetes Care to Announce First Quarter 2025 Financial Results on April 30, 2025
From Tandem Diabetes Care, Inc.
Via Business Wire
Tandem Diabetes Care Announces NEJM Publication of Positive Pivotal Study Outcomes with Control-IQ+ AID Technology in Type 2 Diabetes
From Tandem Diabetes Care, Inc.
Via Business Wire
Tandem Diabetes Care Launches New Control-IQ+ Automated Insulin Delivery Technology in the United States
From Tandem Diabetes Care, Inc.
Via Business Wire
Tandem Diabetes Care Announces Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance
From Tandem Diabetes Care, Inc.
Via Business Wire
Tandem Diabetes Care Announces FDA Clearance of Control-IQ+ Automated Insulin Delivery Technology for People with Type 2 Diabetes
From Tandem Diabetes Care, Inc.
Via Business Wire
Tandem Diabetes Care Announces Upcoming Conference Presentations
From Tandem Diabetes Care, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.